PF-06671008

PF-06671008 is an experimental bispecific antibody developed for the treatment of advanced solid tumors. It is designed to redirect T cells to tumor cells by simultaneously binding to P-cadherin (CDH3) on tumor cells and CD3ε on T cells, thereby inducing targeted cytotoxicity against cancerous tissues. The drug was created using MacroGenics' Dual-Affinity Re-Targeting (DART) platform and further developed in collaboration with Pfizer. Its mechanism involves both antibody-dependent cell cytotoxicity and inhibition of cadherin-mediated cell adhesion, targeting tumors that overexpress P-cadherin—a marker associated with poor prognosis in several cancers such as breast, ovarian, endometrial, colorectal, and pancreatic cancers. Clinical development included phase 1 trials evaluating intravenous and subcutaneous administration in patients with refractory solid tumors; however, the program was terminated due to limited antitumor activity despite manageable safety signals[2][4][5][6].

Other names

P-cadherin CD3 bispecific DARTP-cadherin x CD3 LP-DART